 DJIA Weekly Chart
Q2 Earnings Begin
16 July 2017 Second quarter earnings announcements get underway in earnest this week as we enter the dog days of summer. A lot of traders will be spending their time at the seashore but make no mistake - they'll be monitoring their trades from the seashore pretty closely. The markets have been in an upward trend for quite a while (see chart) and with earnings expected to be good, I expect this upward trend to continue. But as always, it's a market of stocks and some will move higher and some will stumble. Be alert and monitor all your investments because as always, there'll be surprises. Monday Close: The market started off shakey, made an attempt to move higher during the midday, and then lost all its gains in the last two hours. The DJIA ended the day down eight points at 21,629. Earnings continue tomorrow with more volatility expected depending on the company making the announcement. Tuesday Close: All the indexes fell abruptly at the open. The SPX and NASDAQ recovered but the DJIA didn't as it ended the day down 55 points. The SPX and QQQ ended up at new highs but not by very much. Earnings season continues to whipsaw the markets and I expect that to occur for the next week or two as the roll out of announcements continue. Wednesday Close: The indexes rose at a pretty consistent angle as the SPX and NASDAQ once again hit new highs today. With today's move higher the DJIA is on the verge of hitting a new high too. Of particular interest was the strong move higher during the last 10 minutes of the trading day which usually bodes well for a higher opening in the morning. Thursday Close: All three indexes struggled all day and by the end the DJIA was down slightly, the NASDAQ was up slightly, and the SPX was basically flat. It's increasingly becoming a stock picker's market. Mutual Fund owners are making OK money but the traders are making the real money. 
Calithera Biosciences, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase Ib/2 clinical trials for the treatment of solid tumors. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors. In addition, it has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate Opdivo (nivolumab) in combination with CB-839 in clear cell renal cell carcinoma. The company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of CB-1158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Visa and MasterCard
23 July 2017 No explanation is needed to understand a debit and credit card company. We all carry them with us wherever we go. They are now integral to the modern lifestyle. And everyone knows that they're making tons of money. Just look at your recent credit card statement. But they're not cheap. They never were. But at the end of the day they've made a lot of money for their shareholders.
Interesting Charts
18 July 2017 This is a few ideas I looking at for this week. I've become interested simply based on their charts alone. I'll do more research before I trade the long ideas but I'm already positioned to benefit from a fall in the shares of SNAP. So despite my aversion to trading the perils of an American company, I think the money's to be made on the short side. (Full Article) 
An Update on RICK's
14 July 2017 RCI Hospitality has been beefing up it's collection of Gentlemen's Clubs while at the same time continuing to develop its entry into the Casual Dining segment of the restaurant business. And so far its starting to gain traction as plans to expand move forward. But this is a transition period that's setting the groundwork for increasing revenues, earnings and dividends.(Full Article) TTM Technologies
11 July 2017 TTM Technologies, Inc. is one of the world's largest printed circuit board (PCB) manufacturers, focusing on quickturn and technologically advanced PCB, backplane assemblies and electro-mechanical solutions. TTM provides time-to-market and advanced technology products and offers a one-stop manufacturing solution to customers from engineering design to prototype development through final volume production. (Full Article)
TransAct Technologies
22 June 2017 TransAct is a leader in printers, terminals, software and other products for transaction-based industries. These industries include casino and gaming, lottery, food safety, banking, point-of-sale, hospitality, oil and gas, and medical and mobile. TransAct printers and products are designed from the ground up based on market-specific requirements. (Full Article)
Immunomedics
13 June 2017 This Company caught my attention after just one look at the P&F chart. For 7 years there's been resistance near $7 per share as the stock was turned back three times before breaking through. It's now pushed above $8 per share. I believe shares of this company will find support near $7 per share if there's any pullback in the shares and they'll rise to near $12 per share over the next year as earnings turn positive. (Full Article) Legg Mason - A Purely Technical Call
12 June 2017 LM has just pushed through resistance near $38.60 and now has the potential to move up to near $55 per share with little resistance. Earnings next year are expected to be $3.21 and the long term earnings growth is expected to be 17.10%. This is too good to pass up.
Software Stocks of Interest
7 June 2017 The Software Industry is another area moving higher within the rising Technology Sector which also makes it a very nice place to find stocks to buy. Several Companies I'm currently researching and buying are Shopify, Momo, Teladoc, Five9, Pegasystems, Veeva Systems, AppFolio, Paycom, and Evolent Health. Semiconductor Stocks of Interest
6 June 2017 The Semiconductor Industry is an area rising within the rising Technology Sector which makes it a very nice place to find stocks to accumulate. Several companies I'm currently researching and buying are Nvidia, Micron, Ultra Clean Holdings, Applied Materials, Broadcom, Axcelis Technologies, Qorvo, STMicroelectronics, and Skyworks Solutions.  Weekly Chart
Evolent Health
5 June 2017 Evolent Health provides healthcare delivery and payment solutions. The Company supports integrated health systems in migration toward value-based care and population health management and provides customers with a population management platform, integrated data and analytics capabilities, pharmacy benefit management services, and comprehensive health plan administration services. I'm highlighting this company because a move above 26 tomorrow will signal a breakout above resistance.  Daily Chart
Extreme Networks
2 June 2017 Extreme Networks provides software-driven networking solutions for enterprise customers worldwide. The company designs, develops, and manufactures wired and wireless network infrastructure equipment, and develops the software for network management, policy, analytics, security, and access controls. I'm highlighting this company because I initiated a buy-write strategy today for a quick 5% return over a two week period. It can be an effective short term strategy. Allied Motion Technologies
1 June 2017 Allied Motion Technologies produces precision and specialty motion control components and systems for commercial, industrial, aerospace and defense markets. The company provides motion control products and systems as solutions for a range of applications in aerospace and defense, medical, vehicle, commercial, and industrial. (Full Article) Chevron Corporation
30 May 2017 Today oil companies are adjusting to the new equilibrium and are cutting costs to survive and excel in this new paradigm. The stocks are also carving out new support and resistance levels in which to operate. For Chevron, it now looks like the company is finding support near $100 per share. I also expect it to find moderate resistance near $120 per share and then again near $130 per share. (Full Article)
Always Have an Exit Strategy
19 May 2017 The exit strategy is always a mandatory precondition for any trade I enter. All other strategies will have disaster embedded at their core. All other strategies are simply an emotional reaction to events external to the markets. All other strategies will accentuate a reward while ignoring the damage that's incurred by accepting such an extensive implied risk. These are the strategies that I personally refuse to implement into my trading strategy. (Full Article)
|
Investors Read
These Articles More Than 100,000 Times Each Month. 
In 2016 the DJIA ended at 19,762
In 2015 the DJIA ended at 17,425
In 2014 the DJIA ended at 17,823
In 2013 the DJIA ended at 16,576
One Percent per Month
My Investing Strategy A Basic Options Strategy Reviewing Those Dividend Increases Buying Great Companies 
Top 100 Blogs for Dividend Investors
Dennis McCain
DISCLAIMER The Power of Dividends
Understanding Bollinger Bands
|
